26 May 2023
EMA/PDCO/213935/2023
Human Medicines Division

Paediatric Committee (PDCO)

Minutes for the meeting on 24-26 April 2023

Chair: Brian Aylward – Vice-Chair: Sylvie Benchetrit

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

The Chair opened the meeting by welcoming all participants. The meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests concerning the matters for discussion. No new or additional competing interests were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions taken at this meeting were made in the presence of a quorum of members. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda for 24-26 April 2023 meeting was adopted.

1.3. Adoption of the minutes

The minutes for 28-31 March 2023 meeting were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Insulin human (rDNA) - EMEA-003194-PIP02-22

Treatment of type 2 diabetes mellitus

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Note: Withdrawal request received on 17 April 2023

2.1.2. Crofelemer - Orphan - EMEA-003296-PIP01-22

Napo Therapeutics S.p.A.; Treatment of short bowel syndrome

Day 120 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from 4 months to less than 18 years of age, in the condition of treatment of short bowel syndrome was adopted. The PDCO agreed on a waiver in a subset of children from birth to less than 4 months of age on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s). The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan.

2.1.3. Efgartigimod alfa - EMEA-002597-PIP08-22

argenx BV; Treatment of dermatomyositis / Treatment of polymyositis (including antisynthetase syndrome) / Treatment of immune-mediated necrotising myopathy

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from 2 years to less than 18 years, in the condition of treatment of dermatomyositis was adopted. The PDCO agreed on a waiver in the condition of treatment of dermatomyositis in a subset of children from birth to less than 2 years of age on the grounds that the specific medicinal product is likely to be unsafe. The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan.
The PDCO granted a product specific waiver for the entire paediatric population from birth to less than 18 years of age in the conditions of treatment of immune-mediated necrotising myopathy and treatment of polymyositis (including antisynthetase syndrome) on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2.1.4. Asunercept - Orphan - EMEA-003201-PIP01-22

Apogenix AG; Treatment of coronavirus disease 2019 (COVID-19)

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agreed a PIP for asunercept in the condition of treatment of coronavirus disease 2019 (COVID-19) with a deferral in April 2023. The PIP includes one quality study, two clinical studies and a modelling and simulation analysis.

2.1.5. Fosmanogepix - Orphan - EMEA-003280-PIP01-22

Pfizer Europe MA EEIG; Treatment of invasive fungal infections

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO discussed the applicant's responses to the remaining issues that were outlined at Day 90. A positive opinion was adopted covering the entire paediatric population from birth to less than 18 years of age for the treatment of invasive fungal infections. It was stated that the paediatric indications that may eventually be authorised within this wider condition of invasive fungal infections will also be dependent on the indications authorised in adults due to the extrapolation approach. The agreed PIP includes the requirement to develop an age-appropriate oral and an age-appropriate parenteral formulation for use in children below 12 years of age. A toxicity study to investigate potential effects on the central nervous system (CNS) is to be conducted prior to initiation of paediatric clinical trials. The PIP includes two clinical studies (a single-arm pharmacokinetics and safety study in paediatric patients (birth <18 years) who have an indication for antifungal prophylaxis, and a single-arm pharmacokinetics and safety study in paediatric patients (birth <18 years) with invasive fungal infections. An iterative population PK modelling study will be used to support dose finding. The completion of the paediatric studies is deferred.

2.1.6. Obeldesivir - EMEA-003306-PIP01-22

Gilead Sciences International Ltd.; Treatment of coronavirus disease 2019 (COVID-19)

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for the entire paediatric population (from birth to less than 18 years of age), in the condition of treatment of coronavirus disease 2019 (COVID-19) was adopted. The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan.

2.1.7. Humanised VHH-type bispecific antibody against complement component 5 and serum albumin (ALXN1720) - EMEA-003302-PIP01-22

Alexion Europe SAS; Treatment of myasthenia gravis

Day 120 opinion

Neurology

Summary of Committee discussion:

The PDCO adopted a PIP for ALXN1720 for the treatment of myasthenia gravis in paediatric patients from 6 years to less than 18 years of age. A waiver was granted for the age group below 6 years of age based on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s). The completion of both the clinical study and the modelling and simulation study of the agreed PIP is deferred.

2.1.8. Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001) - EMEA-003264-PIP01-22

Hospital Clinic of Barcelona; Treatment of B-lymphoblastic leukaemia/lymphoma

Day 120 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 120, during the April 2023 plenary meeting a request for a paediatric investigation plan for adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001) for the treatment of acute lymphoblastic leukaemia.
The PDCO confirmed all conclusions reached at Day 90, took into consideration information provided by the applicant between Day 90 and Day 120, including during a teleconference, and adopted a positive opinion at Day 120 on a paediatric investigation plan for adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001) for the treatment of B-lymphoblastic leukaemia/lymphoma with a deferral and a waiver for children weighing less than 6 kg on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for these paediatric patients.

2.1.9. Live attenuated respiratory syncytial virus (RSV) - EMEA-003277-PIP01-22

Prevention of respiratory syncytial virus (RSV) diseases

Day 120 opinion

Vaccines

Note: Withdrawal request received on 21 April 2023

2.1.10. Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation - EMEA-003309-PIP01-22

Moderna Biotech Spain, S.L.; Prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV)

Day 120 opinion

Vaccines

Summary of Committee discussion:

In view of the number of outstanding issues the assessment team held a teleconference with the applicant prior to Day 120 discussion in PDCO. During the teleconference, the applicant clarified all outstanding points and introduced some additional changes to the PIP as requested by the PDCO.
Based on the feedback of the assessment team (EMA coordinator, Rapporteur and Peer reviewer) to the PDCO, the Committee adopted a positive opinion for a PIP with a deferral for single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation for all subsets of the paediatric population from 6 weeks of age to 18 years of age in the condition of prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV). A waiver was given for children below 6 weeks of age, on the grounds of expected lack of efficacy. The PIP contains six clinical studies.

2.1.11. Iodine (131I) apamistamab - Orphan - EMEA-003395-PIP01-23

Immedica Pharma AB; Conditioning treatment prior to haematopoietic stem cell transplantation (HSCT) in malignant neoplasms of haematopoietic and lymphoid tissue

Day 60 opinion

Immunology-Rheumatology-Transplantation / Oncology

Note: Withdrawal request received on 24 April 2023

2.1.12. Amphotericin B - Orphan - EMEA-003391-PIP01-23

Matinas BioPharma Holdings Inc.; Treatment of cryptococcosis

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for amphotericin B for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of cryptococcosis on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2.1.13. Carbidopa monohydrate / levodopa - EMEA-003384-PIP02-23

Dizlin Pharmaceuticals AB; Treatment of Parkinson's disease

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application the PDCO agreed with the applicant's request for a waiver.
The PDCO recommended granting a waiver for carbidopa monohydrate / levodopa for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of Parkinson's disease on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2.1.14. Deutetrabenazine - EMEA-002052-PIP02-23

Teva B.V.; Treatment of tardive dyskinesia

Day 60 opinion

Neurology

Summary of Committee discussion:

The PDCO discussed at Day 60, during the April 2023 plenary meeting, an application for a full waiver for deutetrabenazine in the condition of treatment of tardive dyskinesia (TD). Based on the assessment of this application and further discussions at the Paediatric Committee on the general, product unspecific aspects of the unmet need within tardive dyskinesia, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for deutetrabenazine for all subsets of the paediatric population (from birth to 18 years of age) in the condition of treatment of tardive dyskinesia on grounds of lack of significant therapeutic benefit due to lack of study feasibility.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.15. Inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) (SAR443820) - EMEA-003383-PIP02-23

Sanofi Winthrop Industrie; Treatment of amyotrophic lateral sclerosis

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for inhibitor of receptor-interacting serine/threonine-

protein kinase 1 (RIPK1) (SAR443820) for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of amyotrophic lateral sclerosis, on the grounds of lack of significant therapeutic benefit (as clinical trials are not feasible).
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. The PDCO identified amyotrophic lateral sclerosis as an unmet need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.16. Belzutifan - Orphan - EMEA-002619-PIP02-23

Merck, Sharp & Dohme (Europe) Inc; Treatment of von Hippel-Lindau disease (except von Hippel-Lindau disease associated renal cell carcinoma) / Treatment of neuroendocrine tumours (except neuroblastoma)

Day 60 opinion

Oncology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for the proposed medicine for all subsets of the paediatric population (from birth to less than 18 years of age) for the conditions 'treatment of von Hippel-Lindau disease (except von Hippel-Lindau disease associated renal cell carcinoma)' and 'treatment of neuroendocrine tumours (except neuroblastoma)' on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2.1.17. Derivative of (3S,3'S,3a'S,10a'S)-3'-phenyl-3',3a',10',10a'-tetrahydro-1'H-spiro[indoline-3,2'-pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazol]-2-one - EMEA-003260-PIP02-23

Boehringer Ingelheim International GmbH; Treatment of biliary tract cancer

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the April 2023 plenary meeting, a request for a product-specific waiver for a derivative of (3S,3'S,3a'S,10a'S)-3'-phenyl-3',3a',10',10a'-tetrahydro-1'H-spiro[indoline-3,2'-pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazol]-2-one (BI 907828) for the treatment of biliary tract cancer on the grounds that the disease does not occur in paediatric patients.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion at Day 60 on a product specific waiver for this product for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of "treatment of biliary

tract cancer" on the grounds that the disease occurs only in adult populations.
The applicant agreed for the waiver to be extended to all pharmaceutical forms and all routes of administration.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.18. (S)-lactic acid - EMEA-003247-PIP02-23

Stayble Therapeutics AB; Treatment of intervertebral disc disorder

Day 60 opinion

Other

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for (S)-lactic acid for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of intervertebral disc disorder, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the paediatric population from birth to less than 11 years of age, and that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible in the paediatric population from 11 years to less than 18 years of age.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.19. Candesartan (cilexetil) / indapamide - EMEA-003401-PIP01-23

KRKA, d.d., Novo mesto; Treatment of hypertension

Day 30 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for candesartan (cilexetil) / indapamide for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of hypertension.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the

Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.20. Gallium (68Ga) boclatixafortide - EMEA-003408-PIP01-23

PentixaPharm GmbH; Diagnosis of marginal zone lymphoma

Day 30 opinion

Other

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for gallium (68Ga) boclatixafortide for all subsets of the paediatric population (0 to 18 years of age) in the condition of diagnosis of marginal zone lymphoma.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.21. Xylometazoline hydrochloride / sodium hyaluronate - EMEA-003387-PIP01-22

Jadran galenski laboratorij; Treatment of acute rhinosinusitis

Day 60 opinion

Oto-rhino-laryngology

Summary of Committee discussion:

Based on the assessment of this application the PDCO recommended granting a waiver of its own motion for xylometazoline hydrochloride / sodium hyaluronate in the condition of treatment of acute rhinosinusitis for the paediatric population from birth to less than 2 years of age on the grounds that the specific medicinal product is likely to be unsafe and for the paediatric population from 2 years to less than 18 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as the needs are already covered.

2.1.22. Secukinumab - EMEA-000380-PIP10-23

Novartis Europharm Limited; Treatment of polymyalgia rheumatica

Day 30 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the assessment of this application, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for the proposed product for all

subsets of the paediatric population (birth to less than 18 years of age) in the condition of treatment of polymyalgia rheumatica on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations. The applicant agreed to extending the waiver to all pharmaceutical forms and all routes of administration.

2.1.23. Salbutamol sulfate - EMEA-003398-PIP01-23

Teva B.V.; Treatment of asthma

Day 60 opinion

Pneumology - Allergology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO refused the paediatric investigation plan as the product does not bring expected significant therapeutic benefit over existing treatments. Instead, the PDCO granted a product-specific waiver for all subsets of the paediatric population on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

2.2. Opinions on Compliance Check

2.2.1. Dry aqueous extract of *Paullinia cupana* seed / liquid ethanolic extract 30 per cent (w/w) of *Allium cepa* fresh bulb and citrus limon fresh fruit / dry hydroethanolic extract of *Theobroma cacao* seed - EMEA-C-001835-PIP01-15-M05

LEGACY HEALTHCARE (FRANCE) SAS; Treatment of alopecia

Day 60 opinion

Dermatology

Summary of Committee discussion:

The PDCO adopted an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0220/2021) of 9 June 2021.

2.2.2. Efanesoctocog alfa - EMEA-C-002501-PIP01-18-M03

Swedish Orphan Biovitrium; Treatment of haemophilia A

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

The PDCO adopted on 26 April 2023 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0382/2022) of 10 October 2022.

2.2.3. Human thrombin (component 2) / human fibrinogen (component 1) - EMEA-C-001598-PIP01-13-M03

Instituto Grifols, S.A.; Treatment of haemorrhage resulting from a surgical procedure

Day 30 opinion

Other

Summary of Committee discussion:

The PDCO adopted on 26 April 2023 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0052/2021) of 27 January 2021.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. 3,4-Dimethoxy-N-methylbenzohydroxamic acid / deferoxamine mesylate / alpha-ketoglutaric acid / arginine / alanine / glycine / aspartic acid / tryptophan / N-acetyl-histidine (monohydrate) / histidine / calcium chloride (dihydrate) / magnesium chloride (hexahydrate) / potassium chloride / sodium chloride - EMEA-002735-PIP01-19-M01

Dr. Franz Köhler Chemie GmbH; Cardioplegia

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed delay for the completion of the non-clinical studies could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0228/2021 of 9 June 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.2. 3,4-Dimethoxy-N-methylbenzohydroxamic acid / deferoxamine mesylate / alpha-ketoglutaric acid / arginine / alanine / glycine / aspartic acid / tryptophan / N-acetyl-histidine (monohydrate) / histidine / calcium chloride (dihydrate) / magnesium chloride (hexahydrate) / potassium chloride / sodium chloride - EMEA-002735-PIP03-20-M02

Dr. Franz Köhler Chemie GmbH; Heart transplantation

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0484/2021 of 3 December 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.3. Landiolol (hydrochloride) - EMEA-001150-PIP02-13-M05

AOP Orphan Pharmaceuticals GmbH; Treatment of supraventricular arrythmias

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, and further clarifications provided by the applicant after Day 30, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0161/2021 of 16 April 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.4. Treprostinil - EMEA-000207-PIP01-08-M08

Ferrer Internacional, S.A.; Treatment of pulmonary arterial hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, and the clarification received after Day 30 discussion, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0144/2018 of 7 May 2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.5. Brodalumab - EMEA-001089-PIP02-13-M04

LEO Pharma A/S; Treatment of psoriasis

Day 60 opinion

Dermatology

Summary of Committee discussion:

The PDCO rediscussed this application in line with the outcome conclusions of the Day 30 discussion. Based on the assessment of this application and discussions at the Paediatric Committee the PDCO agreed with the applicant's request to extend the current waiver to all subsets of the paediatric population (from birth to less than 18 years of age) for the condition of treatment of psoriasis based on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as the needs are already covered.

2.3.6. Ethinyl estradiol / dienogest - EMEA-002229-PIP02-21-M01

Chemo Research; Treatment of polycystic ovary syndrome

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed delay in timelines for completion of Study 1 and overall completion date of the PIP by 10 months could be accepted due to recruitment challenges.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0031/2022 of 31 January 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.7. Denecimig - EMEA-002762-PIP02-20-M01

Novo Nordisk A/S; Treatment of haemophilia A

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0450/2020 of 1 December 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.8. Lamivudine (3TC) / abacavir (ABC) / dolutegravir (DTG) - EMEA-001219-PIP01-11-M07

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

Infectious Diseases

Note: Withdrawal request received on 13 April 2023

2.3.9. Posaconazole - EMEA-000468-PIP02-12-M08

Merck Sharp & Dohme (Europe), Inc.; Prevention of invasive fungal infections / Treatment of invasive fungal infections

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO reviewed and discussed the conclusions reached at Day 30. The issues and concerns raised then remain valid, and as the applicant did not provide any clarification or justification the Committee cannot endorse these proposed modifications. The changes to Study 13 are acceptable though.
The PDCO therefore adopted a favourable opinion on the modification of some of the key elements of the agreed PIP as set in the Agency's latest decision (P/0196/2022 of 9 June 2022), while keeping the rest of the plan almost unchanged – date of completion of Study 11 has been aligned with that of Study 15. The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.10. Regdanvimab - EMEA-002961-PIP01-21-M02

Celltrion Healthcare Hungary Kft.; Treatment of coronavirus disease 2019 (COVID-19)

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0166/2022 of 13 May 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.11. Sotrovimab - EMEA-002899-PIP01-20-M02

GlaxoSmithKline Trading Services Ltd; Treatment of coronavirus disease 2019 (COVID-19)

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0468/2021 of 12 November 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.12. Tenofovir alafenamide / rilpivirine / emtricitabine - EMEA-001679-PIP01-14-M03

Gilead Sciences International Ltd.; Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes to extend the waiver to all subsets of the paediatric population could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0356/2022 of 11 August 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.13. Efinaconazole - EMEA-001627-PIP01-14-M03

Almirall, S.A.; Treatment of onychomycosis

Day 60 opinion

Infectious Diseases / Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The modification concerned a deletion of Study 4 (pharmacokinetic study in children from 6 years to less than 12 years of age).
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0195/2022 of 10 June 2022).

2.3.14. Ataluren - Orphan - EMEA-000115-PIP01-07-M13

PTC Therapeutics International, Limited; Treatment of dystrophinopathy

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes on the date of completion of Study 7 could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0477/2022 of 2 December 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.15. Cenobamate - EMEA-002563-PIP02-19-M02

Angelini Pharma S.p.A; Treatment of epilepsy

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could

be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0300/2021 of 13 August 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.16. Odronextamab - Orphan - EMEA-003149-PIP01-21-M01

Regeneron Ireland DAC; Treatment of mature B cell malignancies

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0426/2022 of 28 October 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.17. Bilastine - EMEA-000347-PIP02-16-M05

Faes Farma S.A.; Treatment of allergic conjunctivitis

Day 60 opinion

Ophthalmology

Summary of Committee discussion:

In the written response the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0506/2022 of 2 December 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.18. Ponesimod - EMEA-000798-PIP01-09-M04

Janssen-Cilag International NV; Treatment of multiple sclerosis

Day 60 opinion

Other / Neurology

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the April 2023 plenary meeting, a request for modification for ponesimod for the treatment of multiple sclerosis.
The applicant requested to modify clinical study 2, including changing the primary endpoint

and modifying the statistical plan.
The PDCO confirmed all the conclusions reached at Day 30.
Based on the review of the documentation submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be acceptable. Therefore, the PDCO adopted a positive opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0066/2021 of 18 February 2021). The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.19. Adsorbed modified allergen extract of a mixture of 50% *Dermatophagoides pteronyssinus* and 50% *Dermatophagoides farinae* - EMEA-000902-PIP01-10-M01

HAL Allergy BV; Treatment of allergic rhinitis/rhinoconjunctivitis

Day 60 opinion

Pneumology - Allergology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes on the completion dates of the non-clinical studies 1 (36543 MMO) and 2 (DSP-IPL-100109) could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/274/2010 of 3 December 2010).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.20. Baricitinib - EMEA-001220-PIP01-11-M08

Eli Lilly and Company Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)

Day 30 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes, i.e. a minor delay of the completion of Study 6, could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0004/2022 of 31 January 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.21. Upadacitinib - EMEA-001741-PIP01-14-M06

AbbVie Ltd; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)

Day 30 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0510/2021 of 3 December 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.4. Opinions on Re-examinations

No item

2.5. Opinions on Review of Granted Waivers

No item

2.6. Finalisation and adoption of Opinions

No item

2.7. Partial Compliance Checks completed by EMA

The following partial compliance checks have been identified by the PME coordinator and PDCO rapporteur as not needing to be referred to the PDCO for discussion. The PDCO has been informed in writing.

2.7.1. Perflubutane - EMEA-C1-003037-PIP02-22

GE Healthcare AS; Diagnostic evaluation of focal hepatic lesions

Day 30 letter

Diagnostic / Oncology

2.7.2. Crovalimab - EMEA-C1-002709-PIP01-19-M01

F.Hoffmann La Roche GmbH; Treatment of atypical haemolytic uremic syndrome

Day 30 letter

Haematology-Hemostaseology

2.7.3. Sotatercept - EMEA-C1-002756-PIP01-19-M01

Merck Sharp & Dohme B.V.; Treatment of pulmonary arterial hypertension

Day 30 letter

Cardiovascular Diseases

2.7.4. Apremilast - EMEA-C2-000715-PIP03-11-M06

Amgen Europe B.V.; Treatment of psoriasis

Day 30 letter

Immunology-Rheumatology-Transplantation / Dermatology

2.7.5. Avibactam / aztreonam - EMEA-C1-002283-PIP01-17-M04

Pfizer Europe MA EEIG; Treatment of infections caused by aerobic gram-negative bacteria

Day 30 letter

Infectious Diseases

2.7.6. Dermatophagoides pteronyssinus / dermatophagoides farinae - EMEA-C3-001258-PIP01-11-M08

ALK-Abelló A/S; Treatment of asthma

Day 30 letter

Pneumology - Allergology

3. Discussion of applications

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Adapalene, micronised / benzoyl peroxide, hydrous / clindamycin - EMEA-003263-PIP01-22

Treatment of acne vulgaris

Day 90 discussion

Dermatology

3.1.2. Spesolimab - EMEA-002475-PIP03-22

Treatment of Netherton syndrome

Day 90 discussion

Dermatology

3.1.3. EMEA-003019-PIP01-21

Treatment of inborn errors of amino acid metabolism

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.4. Izokibep - EMEA-003325-PIP01-22

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis, and juvenile idiopathic arthritis)

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.5. Lenacapavir / bictegravir - EMEA-003324-PIP01-22

Treatment of human immunodeficiency virus (HIV-1) infection

Day 90 discussion

Infectious Diseases

3.1.6. Posoleucel - Orphan - EMEA-002908-PIP02-22

AlloVir International DAC; Prevention of viral disease in haematopoietic stem cell transplantation (HCT)

Day 90 discussion

Infectious Diseases

3.1.7. 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one - Orphan - EMEA-003268-PIP01-22

Bridge Bio Europe B.V.; Treatment of pantothenate kinase-associated neurodegeneration

Day 90 discussion

Other

3.1.8. Immunoglobulin G4 [228-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal γ4-chain), disulphide with human monoclonal κ-chain, dimer / immunoglobulin G4 [227-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal γ4-chain), disulphide with human monoclonal κ-chain, dimer / immunoglobulin G4 [224-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal γ4-chain), disulphide with human monoclonal κ-chain, dimer - EMEA-003270-PIP01-22

Treatment of allergic rhinitis with or without conjunctivitis in birch tree pollen allergic patients

Day 90 discussion

Pneumology - Allergology

3.1.9. EMEA-003276-PIP01-22

Treatment of post-traumatic stress disorder

Day 90 discussion

Psychiatry

3.1.10. Phuket modRNA / Darwin modRNA / Austria modRNA / Wisconsin modRNA - EMEA-003318-PIP01-22

Prevention of influenza disease

Day 90 discussion

Vaccines

3.1.11. Recombinant human monoclonal antibody to insulin receptor - Orphan - EMEA-002813-PIP01-23

Rezolute (Bio) Ireland Limited; Treatment of congenital hyperinsulinism

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.12. Inebilizumab - EMEA-001911-PIP03-23

Treatment of immunoglobulin G4-related disease (IgG4-RD)

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.13. Upadacitinib - EMEA-001741-PIP09-23

Treatment of systemic lupus erythematosus

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.14. Haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R,4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate (ECT-001-CB) - Orphan - EMEA-003025-PIP03-23

ExCellThera; Treatment in allogeneic haematopoietic stem cell transplantation

Day 60 discussion

Immunology-Rheumatology-Transplantation / Oncology / Haematology-Hemostaseology

3.1.15. Broadly neutralising anti-HIV human monoclonal antibody - EMEA-003392-PIP01-23

Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 discussion

Infectious Diseases

3.1.16. Dordaviprone - Orphan - EMEA-003389-PIP01-23

Chimerix IRL Limited; Treatment of high-grade glioma

Day 60 discussion

Oncology

3.1.17. ALM (Almonds), CAS (Cashews), COD (Codfish), EGG (Egg), HAZ (Hazelnuts), MIL (Milk), PEA (Peanuts), PEC (Pecans), PIS (Pistachios), SAL (Salmon), SES (Sesame Seed), SHR (Shrimp), SOY (Soybeans), WAL (Walnuts), WHE (Wheat) - EMEA-003397-PIP01-23

Treatment of food allergy

Day 60 discussion

Other

3.1.18. EMEA-003394-PIP01-23

Treatment of Duchenne/Becker muscular dystrophy

Day 60 discussion

Other / Neurology

3.1.19. Tanimilast - EMEA-003393-PIP01-23

Treatment of asthma

Day 60 discussion

Pneumology - Allergology

3.1.20. Complement factor B antisense oligonucleotide - EMEA-003396-PIP01-23

Treatment of immunoglobulin A nephropathy (IgAN)

Day 60 discussion

Uro-nephrology

3.1.21. Zapomeran - EMEA-003349-PIP01-22

Prevention of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Vaccines

3.1.22. Influenza virus type B, whole virion, inactivated / influenza virus type A H3N2, whole virion, inactivated / influenza virus type A H1N1, whole virion, inactivated - EMEA-003267-PIP02-23

Prevention of influenza disease

Day 30 discussion

Vaccines

3.1.23. Acetylsalicylic acid / rosuvastatin - EMEA-003410-PIP01-23

Prevention of cardiovascular events

Day 30 discussion

Cardiovascular Diseases

3.1.24. Rivaroxaban / amlodipine - EMEA-003412-PIP01-23

Treatment of hypertension / Prevention of thromboembolic events / Prevention of stroke and systemic embolism

Day 30 discussion

Cardiovascular Diseases

3.1.25. Semaglutide - EMEA-003402-PIP01-23

Treatment of non-alcoholic steatohepatitis (NASH)

Day 30 discussion

Gastroenterology-Hepatology

3.1.26. Tetrahydrouridine / decitabine - Orphan - EMEA-003404-PIP01-23

Novo Nordisk A/S; Treatment of sickle cell disease (SCD)

Day 30 discussion

Haematology-Hemostaseology

3.1.27. EMEA-003350-PIP01-23

Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.28. Belimumab - EMEA-000520-PIP03-23

Treatment of systemic sclerosis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.29. Daxdilimab - EMEA-003411-PIP01-23

Treatment of systemic lupus erythematosus

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.30. Deucravacitinib - EMEA-002350-PIP05-23

Treatment of Sjögren’s syndrome

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.31. Efzofitimod - Orphan - EMEA-003352-PIP02-23

FGK Representative Service GmbH; Treatment of systemic sclerosis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.32. Nipocalimab - Orphan - EMEA-002559-PIP08-23

Janssen-Cilag International NV; Treatment of idiopathic inflammatory myopathies

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.33. Secukinumab - EMEA-000380-PIP11-23

Treatment of rotator cuff tendinopathy

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.34. Niclosamide ethanolamine - EMEA-003407-PIP01-23

Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.1.35. Povidone-iodine - EMEA-003413-PIP01-23

Treatment of common cold

Day 30 discussion

Infectious Diseases

3.1.36. Reparixin - Orphan - EMEA-001693-PIP05-23

Dompé farmaceutici S.p.A.; Treatment of acute respiratory distress syndrome (ARDS)

Day 30 discussion

Infectious Diseases

3.1.37. Bidridistrogene xeboparvovec - Orphan - EMEA-003400-PIP01-23

Sarepta Therapeutics Ireland; Treatment of limb-girdle muscular dystrophy type 2E/R4

Day 30 discussion

Neurology

3.1.38. Opicapone - EMEA-003406-PIP01-23

Treatment of Parkinson’s disease

Day 30 discussion

Neurology

3.1.39. Vemircopan - Orphan - EMEA-002863-PIP02-23

Alexion Europe SAS; Treatment of generalised myasthenia gravis

Day 30 discussion

Neurology

3.1.40. EMEA-003409-PIP01-23

Treatment of solid malignancies

Day 30 discussion

Oncology

3.1.41. Therapeutic DNA plasmid vaccine targeting HPV16 E6 and E7 proteins - EMEA-003403-PIP01-23

Treatment of head and neck cancer / Treatment of cervical cancer

Day 30 discussion

Oncology

3.1.42. mRNA encoding CMV gB / mRNA encoding the gH protein in the CMV glycoprotein complex pentamer / mRNA encoding the UL131A protein in the CMV glycoprotein complex pentamer / mRNA encoding the UL130 protein in the CMV glycoprotein complex pentamer / mRNA encoding the gL protein in the CMV glycoprotein complex pentamer / mRNA encoding the UL128 protein in the CMV glycoprotein complex pentamer - EMEA-003405-PIP01-23

Prevention of cytomegalovirus infection

Day 30 discussion

Vaccines

3.2. Discussions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

3.2.1. Baloxavir marboxil - EMEA-C3-002440-PIP01-18-M04

Roche Registration GmbH; Treatment of influenza

Day 30 discussion

Infectious Diseases

3.2.2. Lenvatinib - EMEA-C-001119-PIP02-12-M08

Eisai GmbH; Treatment of osteosarcoma

Day 30 discussion

Oncology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Azilsartan medoxomil - EMEA-000237-PIP01-08-M11

Takeda Development Centre Europe Ltd; Treatment of hypertension

Day 30 discussion

Cardiovascular Diseases

3.3.2. Macitentan - Orphan - EMEA-001032-PIP01-10-M06

Janssen-Cilag International NV; Treatment of pulmonary arterial hypertension / Treatment of idiopathic pulmonary fibrosis / Treatment of systemic sclerosis

Day 30 discussion

Cardiovascular Diseases

3.3.3. Mavacamten - EMEA-002231-PIP01-17-M01

Bristol-Myers Squibb Pharma EEIG; Treatment of hypertrophic cardiomyopathy

Day 30 discussion

Cardiovascular Diseases

3.3.4. Nemolizumab - EMEA-001624-PIP01-14-M06

Galderma International S.A.S; Treatment of atopic dermatitis

Day 30 discussion

Dermatology

3.3.5. Rocatinlimab - EMEA-002886-PIP01-20-M03

Amgen Europe B.V; Treatment of atopic dermatitis

Day 30 discussion

Dermatology

3.3.6. Recombinant parathyroid hormone: rhPTH (1-84) - Orphan - EMEA-001526-PIP01-13-M06

Takeda Pharmaceuticals International AG Ireland Branch; Hypoparathyroidism

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.7. Potassium chloride / sodium chloride / ascorbic acid / sodium sulfate / sodium ascorbate / polyethylene glycol 3350 - EMEA-001705-PIP02-15-M04

Norgine Limited; Bowel cleansing prior to clinical procedures

Day 30 discussion

Gastroenterology-Hepatology

3.3.8. Efgartigimod alfa - Orphan - EMEA-002597-PIP04-21-M01

argenx BV; Treatment of immune thrombocytopenia

Day 30 discussion

Haematology-Hemostaseology

3.3.9. Ixekizumab - EMEA-001050-PIP02-18-M02

Eli Lilly and Company (Ireland) Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondyloarthritis and juvenile idiopathic arthritis)

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.10. Tenofovir alafenamide / emtricitabine / bictegravir - EMEA-001766-PIP01-15-M05

Gilead Sciences International Ltd.; Treatment of human immunodeficiency virus (HIV) infection

Day 30 discussion

Infectious Diseases

3.3.11. Soticlestat - Orphan - EMEA-002572-PIP02-19-M03

Takeda Pharma A/S; Dravet syndrome / Lennox-Gastaut syndrome

Day 30 discussion

Neurology

3.3.12. (4S,7aR,9aR,10S,11E,14S,15R)-6'-chloro-10-methoxy-14,15-dimethyl-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,7H-spiro[1,19-ethenocyclobuta[i][1,4]oxazepino[3,4f][1,2,7]thiadiazacyclohexadecine-4,1'-naphthalen]-18(17H)-one 16,16-dioxide (AMG 176) - EMEA-002631-PIP01-19-M02

Amgen Europe BV; Treatment of acute myeloid leukaemia

Day 30 discussion

Oncology

3.3.13. Magrolimab - Orphan - EMEA-002819-PIP01-20-M01

Gilead Sciences International Ltd; Treatment of myelodysplastic syndromes (including juvenile myelomonocytic leukaemia) / Treatment of acute myeloid leukaemia

Day 30 discussion

Oncology

3.3.14. Talimogene laherparepvec - EMEA-001251-PIP01-11-M06

Amgen Europe B.V.; Treatment of melanoma

Day 30 discussion

Oncology

3.3.15. Gilteritinib (as fumarate) - Orphan - EMEA-002064-PIP01-16-M05

Astellas Pharma Europe B.V.; Treatment of acute myeloid leukaemia

Day 30 discussion

Oncology / Haematology-Hemostaseology

3.3.16. Ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA-002324-PIP01-17-M04

Vertex Pharmaceuticals (Ireland) Limited; Treatment of cystic fibrosis

Day 30 discussion

Other / Pneumology - Allergology

3.3.17. Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA-002330-PIP01-18-M03

Pfizer Europe MA EEIG; Prevention of disease caused by *Streptococcus pneumoniae*

Day 30 discussion

Vaccines

3.3.18. Modified vaccinia Ankara - Bavarian Nordic virus (smallpox) - EMEA-001161-PIP02-11-M03

Bavarian Nordic A/S; Prevention of smallpox, mpox and related orthopoxvirus infection

Day 30 discussion

Vaccines

3.3.19. NVX-CoV2373 - EMEA-002941-PIP01-20-M03

Novavax CZ, a.s.; Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Vaccines

3.3.20. Recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510) - EMEA-003115-PIP01-21-M01

SK Chemicals GmBH; Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Vaccines

4. Nominations

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

4.1. List of submissions of applications with start of procedure 24 April 2023 for Nomination of Rapporteur and Peer reviewer

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver

No item

4.3. Nominations for other activities

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

No item

5.2. Final Scientific Advice (Reports and Scientific Advice letters)

No item

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

No item

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

No item

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. PDCO membership

None

9.1.2. Vote by Proxy

None

9.1.3. Strategic Review and Learning Meeting (SRLM)

No item

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of Committee discussion:

The list of PIP-related CHMP procedures starting in March 2023, was presented to the PDCO members.

Feedback on the ongoing CHMP procedures was provided to the Committee by the nominated PDCO experts.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Party: D30 Products identified

PDCO member: Karen van Malderen

Summary of Committee discussion:

The Vice-Chair of the Non-clinical Working Party (NcWP) identified the products which will require NcWP evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward (*ad interim*)

Summary of Committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require FWG evaluation and discussion.

9.3.3. Patients and Consumers Working Party (PCWP)/Healthcare Professionals Working Party (HCPWP)

No item

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

No item

9.5. Cooperation with International Regulators

9.5.1. Paediatric Cluster Teleconference

Summary of Committee discussion:

The March 2023 minutes and April 2023 agenda and minutes of the cluster were shared with the PDCO members for information.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No item

9.7. PDCO work plan

No Item

9.8. Planning and reporting

9.8.1. EMA Business Pipeline activity and Horizon scanning

No item

10. Any other business

10.1. ACT EU multi-stakeholder platform

Summary of Committee discussion:

Presentation on the Accelerating Clinical Trials in the EU (ACT EU) initiative was shared with PDCO with a particular focus on the kick-off meeting of the multi-stakeholder platform which will take place on 22-23 June 2023.

10.2. Concept paper on the need to update the inflammatory bowel disease (IBD) guideline

Summary of Committee discussion:

The potential need to update the paediatric part of the Crohn's disease guideline was discussed and the next steps planned.

10.3. COVID-19 update

Summary of Committee discussion:

The PDCO was updated on COVID vaccines and on avian influenza.

10.4. EU Network Training Centre (EU NTC): Paediatric curriculum and rollout of Learning & Development toolkit

Summary of Committee discussion:

EMA provided an overview of the Paediatric curriculum, which was last updated in 2017 and asked for volunteers to form a Paediatric curriculum steering group. In particular, EMA asked for a volunteer to be appointed as PDCO curriculum lead. In this role, he/she will:

- Act as the main point of contact between the PDCO and the EU NTC team;
- Lead and coordinate discussions at PDCO level on activities relating to the identification of learning needs and development of training.

EMA also asked for volunteers among the PDCO members and alternates to support the PDCO curriculum lead in order to form a curriculum steering group.

In addition, EMA presented the Learning & Development (L&D) Toolkit, an interactive guide to support the work of the EU NTC curriculum steering groups.

The PDCO was informed that the EU NTC Training Steering Group co-chairs, will present to HMA the work on the Paediatric curriculum as part of a status update on the various EU NTC training curricula.

10.5. New Experts Management tool

Summary of Committee discussion:

A short update on the new expert management tool was given. Major questions were addressed, as the possibility to choose certain NCAs or issues related to certain free text fields.

10.6. Prerequisites for PIP modification of an approved PIP

Summary of Committee discussion:

The Bundesverband der Pharmazeutischen Industrie (BPI) (German manufacturers' representative) submitted to the PDCO a formal request to seek clarification on the legal basis of PDCO requirement to modify allergen PIPs only when recruitment of paediatric subjects in the long-term efficacy trials has been started.

10.7. Revision of EMA policy 0044 on handling of competing interests of scientific committees' members and experts

Summary of Committee discussion:

A short summary of the updated policy 0044 was presented. The main changes e.g. the inclusion of the need to declare interest in the medical device industry, were discussed and pointed out.

10.8. Upcoming Innovation Task Force (ITF) meetings

Summary of Committee discussion:

Three ITF meetings taking place in May 2023 were presented for information.

11. Breakout sessions

11.1. Neonatology

Summary of Committee discussion:

The group discussed topics around modelling and simulation and clinical trials for treatment of seizures in neonates.

11.2. Vaccines

Summary of Committee discussion:

The discussion was focused on COVID vaccines boosters in children, with specific focus on comparator groups.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 24-26 April 2023 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Brian Aylward	Chair	Ireland	No interests declared	
Marleen Renard	Member	Belgium	No participation in discussion, final deliberations and voting on:	2.3.9. Posaconazole - EMEA-000468-PIP02-12-M08
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Zena Gunther	Member	Cyprus	No interests declared	
Tereza Bazantova	Alternate	Czechia	No interests declared	
Nanna Borup Johansen	Member	Denmark	No interests declared	
Louisa Braun Exner	Alternate	Denmark	No interests declared	
Pauliina Lehtolainen-Dalkilic	Member	Finland	No interests declared	
Anne Paavola	Alternate	Finland	No interests declared	
Sylvie Benchetrit	Member (Vice-Chair)	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Adrienn Horváth	Member	Hungary	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Cinzia Ciceroni	Alternate	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Carola de Beaufort	Member	Luxembourg	No restrictions applicable to this meeting	
Olivier Moes	Alternate	Luxembourg	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Herbert Lenicker	Alternate	Malta	No interests declared	
Roderick Houwen	Member	Netherlands	No restrictions applicable to this meeting	
Maaike van Dartel	Alternate	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No restrictions applicable to this meeting	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Sara Vennberg	Member	Sweden	No interests declared	
David Khan	Alternate	Sweden	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jaroslav Sterba	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Tomasz Grybek	Member	Patients' Organisation Representative	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
María Estela Moreno Martín	Expert - via telephone	Spain	No interests declared	
Meeting run with support from relevant EMA staff				

Experts were evaluated against the agenda topics or activities they participated in.

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (*section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs*)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (*section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check*)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (*section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP*)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (*section 6 Discussion on the applicability of class waiver*)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (*section 8*)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/